Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Home/Biomarker

KRAS G12C

Gene: KRAS · Type: mutation

Indications: Non-small cell lung cancer

Sensitivity Resistance CIViC Context

Linked CIViC Profile: KRAS G12C

Evidence Level Distribution

Level A: 3Level B: 7Level C: 1Level D: 7

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sotorasib	5
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Divarasib	4
A	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab,Adagrasib	4
A	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab,Sotorasib	4
D	Predictive	Supports	Sensitivity/Response	Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853	3
B	Predictive	Supports	Resistance	Colorectal Cancer	Erlotinib,Gefitinib	3
B	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		3
C	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab	3
B	Predictive	Supports	Resistance	Colorectal Cancer	Chemotherapy,Cetuximab	3
D	Predictive	Supports	Sensitivity/Response	Solid Tumor	Adagrasib	3
B	Diagnostic	Supports	Positive	Lung Cancer		2
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	2
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Selumetinib,Dactolisib	2
B	Predictive	Supports	Resistance	Lung Cancer	Gefitinib	2
D	Predictive	Supports	Resistance	Multiple Myeloma	Melphalan	2
D	Predictive	Supports	Resistance	Multiple Myeloma	Melphalan	2
D	Predictive	Supports	Resistance	Colorectal Cancer	Regorafenib Anhydrous	2
D	Predictive	Supports	Resistance	Multiple Myeloma	Melphalan	0